Praedicare Inc. receives grant to evaluate potential new drug regimens for TB

DALLAS, June 17, 2021 -- Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicare’s in vitro hollow fiber model of tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.